Physician profile
Gary A Belaga
NPI 1720196744
$12,162.06
in general payments reported to CMS, 2019-2025
33 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,263 · 2020: $2,215 · 2021: $2,174 · 2022: $1,341 · 2023: $1,712 · 2024: $1,267 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,170.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,985.88 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Allergan, INC. | $1,350.01 | 2019-2022 | |
| Bausch Health US, LLC | $1,055.79 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $815.66 | 2019-2025 | Ajovy, Austedo Xr |
| Upsher-Smith Laboratories LLC | $697.96 | 2019-2023 | |
| Pfizer INC. | $661.33 | 2019-2025 | |
| Lilly USA, LLC | $579.04 | 2019-2024 | Emgality, Reyvow |
| Amgen INC. | $473.57 | 2019-2022 | |
| Eisai INC. | $444.58 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $403.87 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $284.51 | 2022 | |
| Lundbeck LLC | $278.95 | 2020-2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $266.54 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $226.22 | 2023-2025 | Ztlido |
| Impel Pharmaceuticals INC. | $222.07 | 2022-2023 | Trudhesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $199.29 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $195.30 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $188.05 | 2021-2024 | Xeomin |
| Axsome Therapeutics, INC. | $184.48 | 2025 | Symbravo |
| Ucb, INC. | $102.70 | 2019 | |
| Currax Pharmaceuticals LLC | $95.43 | 2020-2024 | Onzetra Xsail |
| Assertio Therapeutics, INC. | $72.52 | 2019 | |
| Avanir Pharmaceuticals, INC. | $66.07 | 2019 | |
| Neurelis, INC. | $63.27 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $47.29 | 2019 | |
| Supernus Pharmaceuticals, INC. | $45.47 | 2019-2020 | |
| Promius Pharma LLC | $42.58 | 2019 | |
| Saluda Medical Americas, INC. | $28.47 | 2024 | Evoke |
| Endo Pharmaceuticals INC. | $24.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.68 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.99 | 2019 | |
| Shire North American Group INC | $11.26 | 2019 | |
| Galderma Laboratories, L.P. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Belaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.